NCT04308174: Neoadjuvant Gemcitabine Plus Cisplatin With or Without Durvalumab in Resectable Biliary Tract Cancer
- State
- Under way
- Phase
- Phase 2
- People
- 45 taking part
- Started
- 20 May 2020
- Primary completion
- 30 Jun 2023
- Arms
- Durvalumab + Gem/Cis
- Results
- None posted
- 13 Mar 2020: Trial registered
- 20 May 2020: Trial started